Adagrasib
Approved medicineAlso known as KRAS G12C inhibitor MRTX849, Krazati, ((2s)-4-(7-(8-chloronaphthalen-1-yl)-2-(((2s)-1- methylpyrrolidin-2-yl)methoxy)-5,6,7,8- tetrahydropyrido(3,4-d)pyrimidin-4-yl)-1-(2-fluoroprop2-enoyl)piperazin-2-yl)acetonitrile, 2-piperazineacetonitrile, 4-(7-(8-chloro-1-naphthalenyl)-5,6,7,8-tetrahydro-2-(((2s)-1-methyl-2-pyrrolidinyl)methoxy)pyrido(3,4-d)pyrimidin-4-yl)-1-(2-fluoro-1-oxo-2-propen-1-yl)-, (2s)-.
Recent clinical, regulatory, research and industry developments relating to this drug.
Genomically-Guided Treatment Trial in Brain Metastases
Krazati withdrawal completed; Wegovy trial meets endpoint for kids ages 6 to 12
Label change: ADAGRASIB (NDA216340)
Label change: ADAGRASIB (NDA216340)
Indication expansion: ADAGRASIB (NDA216340)
Conditional marketing authorisation: Krazati (EMA)
Adagrasib in Advanced Solid Tumors Harboring a <i>KRAS</i><sup><i>G12C</i></sup> Mutation.
Adagrasib with or without Cetuximab in Colorectal Cancer with Mutated <i>KRAS</i> G12C.
Profile
Canonical identifiers, marketed brand names and mechanism, resolved across RxNorm, ChEMBL and ATC.
Pharmacology & targets
Known molecular targets and mechanisms supported by curated pharmacology databases.
Regulatory timeline
The complete regulatory record, grouped by authority — approvals, safety advisories and label changes. Each authority shows its most recent events; expand one to read its full history.
Indication: Krazati as monotherapy is indicated for the treatment of adult patients with advanced non-small cell lung cancer (NSCLC) with KRAS G12C mutation and disease progression after at… Show full indicationShow less
Krazati as monotherapy is indicated for the treatment of adult patients with advanced non-small cell lung cancer (NSCLC) with KRAS G12C mutation and disease progression after at least one prior systemic therapy.
Data from the U.S. Food and Drug Administration (U.S. Food and Drug Administration), public domain (CC0).
Contains information from the European Medicines Agency (European Medicines Agency), © EMA, reused under CC BY 4.0.
Clinical trials
The current development programme across all trial phases — status mix, phase distribution and the late-stage studies shaping the evidence base.
Late-stage studies
Phase III+ trials still open or recently active — where late-stage evidence is being generated.
Recent completions
Trials that read out recently, adding to the completed evidence base.
Research activity
Key research shaping understanding of this drug, combining the latest publications with the most influential evidence.
Major research themes8
Journals, researchers & institutions
- The New England journal of medicine2
- Cancer discovery1
- Journal of clinical oncology : official journal of the American Society of Clinical Oncology1
- Der-Torossian H4
- Velastegui K4
- Barve M3
- Bekaii-Saab TS3
- Pelster MS3
- Sabari JK3
- Spira AI3
- Yaeger R3
- Memorial Sloan Kettering Cancer Center3
- Mayo Clinic2
- Perlmutter Cancer Center2
- Sarah Cannon Research Institute2
- The University of Texas MD Anderson Cancer Center2
- Cleveland Clinic1
Related diseases
Regulator-approved indications and conditions co-mentioned with this drug across the research literature. Number shows shared papers.
Related drugs
Drugs sharing diseases, protein targets and literature with this one. Ranked by graph evidence (shared targets + diseases weighted above co-mentions).
Studied across 2 of the same disease areas as Adagrasib in the shared literature.
- RxNorm (U.S. National Library of Medicine) — drug identity
- ChEMBL (EMBL-EBI) & UniProt — pharmacology and targets
- Europe PMC — research literature
- ClinicalTrials.gov — clinical trials
- Regulatory event sources are credited in the Regulatory Timeline above.